Oncimmune Holdings PLC EarlyCDT®-Lung Kit Distribution Agreements

TIDMONC

Oncimmune Holdings PLC

19 September 2017

19 September 2017

Oncimmune Holdings plc

("Oncimmune" or the "Company")

First Distribution Agreements Signed for EarlyCDT(R)-Lung Kit in Europe

Exclusive agreements for Denmark, Norway and Sweden with aggregate minimum sales commitment of approximately GBP500,000

Nottingham, UK - 19 September 2017: Oncimmune Holdings plc (AIM: ONC.L), a leading early cancer detection company developing and commercialising its proprietary EarlyCDT(R) platform technology, today announces it has signed three new exclusive distribution agreements for its EarlyCDT(R)- Lung test with LabLab ApS, Diuvita Diagnostics AS and XboXLab AB in Denmark, Norway and Sweden respectively.

The agreements allow for the sale of the CE marked kit to local laboratories and as a central laboratory test. The three agreements are for an initial term of three years and include minimum sales commitments of approximately GBP500,000. First sales are expected to commence late in 2017/early 2018.

Geoffrey Hamilton-Fairley, CEO of Oncimmune, commented: "These distribution agreements, which we anticipate to be the first of many across Europe, give us full coverage of the Scandinavian region where we have received a great deal of interest in our EarlyCDT(R)-Lung test. As part of the strategy indicated at the time of our IPO, we outlined our plan to grow into multiple regions with multiple products and these latest agreements not only show our commitment to that strategy but also indicate the strength and potential of our EarlyCDT(R)-Lung test and kit."

For further information:

Oncimmune Holdings plc

Geoffrey Hamilton-Fairley, Chief Executive Officer

[e-mail]

Zeus Capital Limited

Phil Walker, Giles Balleny, Hugh Kingsmill Moore

[phone]

Media enquiries:

Consilium Strategic Communications

Chris Gardner, Matthew Neal, Lindsey Neville

[e-mail]

[phone]

About Oncimmune

Oncimmune is a leading early cancer detection company developing and commercialising its proprietary EarlyCDT(R) platform technology. Oncimmune has pioneered the development of autoantibody tests that can detect cancer up to four years earlier than other methods and can be applied to a very wide range of solid tumour types. The Company's first product, EarlyCDT(R)-Lung, was launched in 2012, as a CLIA test in the USA and since then over 150,000 commercial tests have been sold. EarlyCDT(R)-Lung is available through physicians in the US and also privately in the UK and other regions. EarlyCDT(R)-Lung is being used in the largest ever randomised trial for the early detection of lung cancer using biomarkers. The NHS Scotland ECLS study of over 12,000 high-risk smokers is now fully recruited and in the final follow up stage. EarlyCDT(R) tests for liver and ovarian cancer are in development.

Oncimmune, headquartered in Nottingham, United Kingdom with testing facilities in the US, joined AIM in May 2016 under the ticker ONC.L. For more information visit www.oncimmune.com

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRAOKFDQKBKBOCD

(END) Dow Jones Newswires

September 19, 2017 02:01 ET (06:01 GMT)